MedPath

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTES OF HEALTH logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary, Private
Established
1948-01-01
Employees
1K
Market Cap
-
Website
http://www.nidcr.nih.gov
Clinical Trials
Related News

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Phase 1
Completed
Conditions
Neurofibromatosis Type I
Plexiform Neurofibroma
First Posted Date
2008-08-01
Last Posted Date
2019-12-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
9
Registration Number
NCT00727233
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The Effect of Vitamin D and Calcium on Bone in Pediatric HIV

Phase 2
Completed
Conditions
HIV Infection
Bone Mass
Interventions
Dietary Supplement: cholecalciferol plus calcium carbonate
First Posted Date
2008-07-29
Last Posted Date
2010-01-15
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
59
Registration Number
NCT00724178
Locations
πŸ‡ΊπŸ‡Έ

St.Luke's-Roosevelt Hospital Cener, New York, New York, United States

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2
Completed
Conditions
Recurrent Endometrial Carcinoma
Interventions
Biological: bevacizumab
First Posted Date
2008-07-28
Last Posted Date
2019-07-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
53
Registration Number
NCT00723255
Locations
πŸ‡ΊπŸ‡Έ

Hartford Hospital, Hartford, Connecticut, United States

πŸ‡ΊπŸ‡Έ

The Hospital of Central Connecticut, New Britain, Connecticut, United States

πŸ‡ΊπŸ‡Έ

Washington Hospital Center, Washington, District of Columbia, United States

and more 38 locations

Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease

Withdrawn
Conditions
Graft-Versus-Host-Disease
First Posted Date
2008-07-28
Last Posted Date
2017-10-06
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registration Number
NCT00723593

TODAY Genetics Study

Completed
Conditions
Type 2 Diabetes
First Posted Date
2008-07-25
Last Posted Date
2021-08-04
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
2654
Registration Number
NCT00722397
Locations
πŸ‡ΊπŸ‡Έ

UAMS Arkansas Children's Hospital, Little Rock, Arkansas, United States

πŸ‡ΊπŸ‡Έ

Childrens Hospital Los Angeles, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

UCSD Rady Children's Hospital, San Diego, California, United States

and more 22 locations

Resveratrol in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy, no Evidence of Disease
Interventions
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2008-07-25
Last Posted Date
2014-10-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT00721877
Locations
πŸ‡ΊπŸ‡Έ

Arizona Cancer Center - Tucson, Tucson, Arizona, United States

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Phase 1
Completed
Conditions
Adult Synovial Sarcoma
Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Childhood Angiosarcoma
Childhood Desmoplastic Small Round Cell Tumor
Childhood Epithelioid Sarcoma
Childhood Fibrosarcoma
Childhood Leiomyosarcoma
Childhood Liposarcoma
Childhood Malignant Mesenchymoma
Childhood Malignant Peripheral Nerve Sheath Tumor
Interventions
Biological: Cixutumumab
Other: Laboratory Biomarker Analysis
First Posted Date
2008-07-22
Last Posted Date
2016-05-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00720174
Locations
πŸ‡ΊπŸ‡Έ

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Decatur Memorial Hospital, Decatur, Illinois, United States

πŸ‡ΊπŸ‡Έ

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 10 locations

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
First Posted Date
2008-07-22
Last Posted Date
2020-04-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
63
Registration Number
NCT00720109
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 131 locations

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Interventions
Other: laboratory biomarker analysis
First Posted Date
2008-07-22
Last Posted Date
2015-01-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
11
Registration Number
NCT00719901
Locations
πŸ‡ΊπŸ‡Έ

Mayo Clinic, Rochester, Minnesota, United States

Experimental Device to Improve Colonoscopy

Completed
Conditions
Colon Cancer Screening
Looping
Colonoscopy
Prevent Looping
First Posted Date
2008-07-22
Last Posted Date
2020-03-24
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
42
Registration Number
NCT00719641
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy